Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Mallinckrodt
Accenture
Dow
Argus Health
US Army
AstraZeneca
Harvard Business School
Daiichi Sankyo
Queensland Health

Generated: January 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,999,379

« Back to Dashboard

Summary for Patent: 8,999,379
Title:Transparent transdermal nicotine delivery devices
Abstract: A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%.
Inventor(s): Gale; Robert M. (Los Altos, CA)
Assignee: ALZA Corporation (Vacaville, CA)
Application Number:14/192,811
Patent Claims: 1. A method for smoking cessation therapy, comprising: providing a transdermal nicotine delivery device comprising a backing layer formed from a material selected from the group consisting of PET/EVA laminates, HDPE/EAA/nylon/EAA multilaminate and a film comprising a graft copolymer formed from about 73-77% acrylonitrile and from about 23-27% methyl acrylate copolymerized in the presence of about 8-10 parts by weight of butadiene/acrylonitrile copolymers containing approximately 70% by weight of polymer units derived from butadiene, and a drug reservoir layer containing nicotine carried by the backing layer, wherein the device has an Opacity Index of less than 48.6% to permit the skin of a subject to which it is applied to be visible through the device; and applying the device to the skin of a subject.

2. The method according to claim 1, wherein the device further comprises an adhesive for maintaining the device in nicotine transmitting relationship with the skin of a subject.

3. The method according to claim 1, further comprising maintaining the device on the skin to deliver nicotine for 18-24 hours.

4. The method according to claim 1, wherein the backing has a nicotine permeability of less than 1.0 .mu.g/cm.sup.2/hr.

5. The method according to claim 1, wherein the backing has a nicotine permeability of less than 0.5 .mu.g/cm.sup.2/hr.

6. The method according to claim 1, wherein the backing has a solubility for nicotine of less than 1 wt %.

7. The method according to claim 1, wherein the backing has a solubility for nicotine of less than 0.1 wt %.

8. The method according to claim 1, wherein the device has an Opacity Index of less than 35.11%.

9. The method according to claim 1, wherein the device has an Opacity Index of less than 20%.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Federal Trade Commission
Julphar
Daiichi Sankyo
Chubb
Citi
Dow
Teva
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot